| Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosu NCT06752876 | Caribou Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | Saphnelo Use in Females of Child-bearing Potential NCT07431775 | AstraZeneca | — |
| Recruiting | Safety and Efficacy of ONT01 in Lupus NCT07107659 | Hospital for Special Surgery, New York | EARLY_Phase 1 |
| Not Yet Recruiting | Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis NCT07493655 | Federal University of Maranhao | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20- NCT06984341 | Genentech, Inc. | Phase 1 |
| Not Yet Recruiting | Immun4Cure Cohort of Autoimmune Diseases NCT07515638 | University Hospital, Montpellier | — |
| Not Yet Recruiting | Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases NCT07523282 | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 |
| Not Yet Recruiting | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) NCT07409181 | Boehringer Ingelheim | Phase 2 |
| Not Yet Recruiting | A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus NCT07509892 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Not Yet Recruiting | CHT105 for the Treatment of Refractory Lupus Nephritis NCT07517536 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N/A |
| Not Yet Recruiting | A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic NCT07430306 | AstraZeneca | Phase 3 |
| Not Yet Recruiting | A Study of E6742 in Participants With Systemic Lupus Erythematosus NCT07515014 | Eisai Co., Ltd. | Phase 2 |
| Recruiting | MTS109 in Patients With Refractory Autoimmune Diseases NCT07526350 | Shanghai Changzheng Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. NCT07408908 | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 |
| Recruiting | Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases NCT05029336 | Stephan Grupp MD PhD | Phase 2 |
| Not Yet Recruiting | UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases NCT07410377 | The Affiliated Hospital of Xuzhou Medical University | EARLY_Phase 1 |
| Not Yet Recruiting | A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus NCT07299422 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | Alnuctamab for Refractory SLE (LATTE Study) NCT07219563 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Recruiting | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatm NCT07246096 | Changhai Hospital | EARLY_Phase 1 |
| Recruiting | A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) NCT07363590 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) NCT07371468 | GlaxoSmithKline | Phase 1 |
| Recruiting | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheum NCT07276958 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus NCT07405970 | Beijing Mabworks Biotech Co., Ltd. | Phase 3 |
| Not Yet Recruiting | A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept a NCT07069972 | Yipeng Liu | — |
| Recruiting | Study of CD19 CAR-T Therapy for Refractory SLE NCT07403097 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Not Yet Recruiting | Anifrolumab Pregnancy Study NCT07049653 | AstraZeneca | — |
| Not Yet Recruiting | A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases NCT07212322 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Anifrolumab Malignancy and Serious Infections Study NCT07000110 | AstraZeneca | — |
| Recruiting | Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE NCT07318259 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users NCT06594068 | AstraZeneca | Phase 4 |
| Not Yet Recruiting | Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies NCT07251179 | University Hospital, Strasbourg, France | — |
| Recruiting | Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07331467 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | A Phase I Study to Assess LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus NCT07323173 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 |
| Recruiting | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evalu NCT07260877 | Ventus Therapeutics U.S., Inc. | Phase 2 |
| Recruiting | Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants NCT07201558 | AstraZeneca | Phase 1 |
| Recruiting | Creating Health Course Study for People With Rheumatological Conditions NCT07180537 | Terry L. Wahls | N/A |
| Not Yet Recruiting | Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus NCT07260942 | University Hospital, Bordeaux | N/A |
| Active Not Recruiting | A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupu NCT07053137 | Yipeng Liu | — |
| Recruiting | An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07236762 | China Immunotech (Beijing) Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | The Anifrolumab PRIM Program NCT06795893 | AstraZeneca | — |
| Recruiting | Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE NCT07233642 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Recruiting | UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis NCT07109986 | Nanjing IASO Biotechnology Co., Ltd. | Phase 1 |
| Enrolling By Invitation | Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Base NCT07221565 | Truway Health, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms NCT07203157 | NYU Langone Health | N/A |
| Not Yet Recruiting | EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases NCT07077304 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Study of CM355 in Patients With Systemic Lupus Erythematosus NCT07104344 | Second Xiangya Hospital of Central South University | N/A |
| Not Yet Recruiting | Development of a Dietary Intervention Model Based on Genetic Data as an Implementation of a Healthy Lifestyle NCT07183007 | Indonesia University | N/A |
| Completed | Respiratory Function, Physical Activity and Fatigue in SLE NCT07193745 | Melis Usul | — |
| Not Yet Recruiting | The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus NCT07136337 | Assiut University | N/A |
| Not Yet Recruiting | Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in Egypt NCT07144514 | AstraZeneca | — |
| Recruiting | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusio NCT06977724 | AbbVie | Phase 1 |
| Recruiting | Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease NCT07077486 | Tongji Hospital | Phase 4 |
| Recruiting | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases NCT06570798 | Amgen | Phase 2 |
| Recruiting | A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE) NCT07011043 | Climb Bio, Inc. | Phase 1 |
| Active Not Recruiting | Lupus Arthritis: Muscoloskeletal Ultrasound as Clinical Outcome of Peripheral Blood and Synovial Deep Phenotyp NCT07102238 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Enrolling By Invitation | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases NCT07038447 | Kite, A Gilead Company | Phase 1 |
| Recruiting | Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users NCT06659029 | AstraZeneca | — |
| Recruiting | " TREX1 Gene Mutations and Their Role in Systemic Lupus Erythematosus NCT07397728 | South Valley University | — |
| Recruiting | A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus NCT06857214 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus NCT07001839 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06970951 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Transcutaneous Vagus Nerve Stimulation in SLE NCT06987565 | Northwell Health | Phase 2 |
| Recruiting | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Partic NCT06916806 | AstraZeneca | Phase 1 |
| Not Yet Recruiting | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases NCT06978738 | Changzhou No.2 People's Hospital | Phase 1 |
| Active Not Recruiting | A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With S NCT06544330 | Synthekine | Phase 1 |
| Recruiting | Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE NCT06934447 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Withdrawn | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythem NCT06429800 | Atara Biotherapeutics | Phase 1 |
| Recruiting | A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Ar NCT06917742 | Capstan Therapeutics | Phase 1 |
| Recruiting | UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus NCT06920433 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus NCT06340750 | Luminary Therapeutics | Phase 1 |
| Active Not Recruiting | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases NCT07155369 | The Affiliated Hospital of Xuzhou Medical University | N/A |
| Not Yet Recruiting | Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatig NCT06784076 | NHS Greater Glasgow and Clyde | — |
| Recruiting | Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） NCT06801119 | Shenzhen MagicRNA Biotechnology Co., Ltd | Phase 1 |
| Active Not Recruiting | Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study NCT06898489 | Yijun Luo | — |
| Not Yet Recruiting | Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE) NCT06859931 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangi NCT05504187 | Kira Pharmacenticals (US), LLC. | Phase 2 |
| Not Yet Recruiting | Clinical Study of ZM001 Injection in the Treatment of Refractory Systemic Lupus Erythematosus NCT06852573 | Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 1 |
| Recruiting | CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus NCT06349343 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | HLA Antibodies in Systemic Lupus Erythematosus NCT06921239 | Centre Hospitalier Universitaire, Amiens | — |
| Active Not Recruiting | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases NCT06255028 | Century Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE) NCT06791772 | Keymed Biosciences Co.Ltd | Phase 2 |
| Withdrawn | A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupu NCT06238531 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 1 |
| Recruiting | UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients NCT06737380 | LiveKidney.Bio | Phase 1 |
| Recruiting | Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases NCT06614270 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique NCT06365359 | University Hospital Center of Martinique | — |
| Withdrawn | Phase 1b/2a in SLE With Budoputug NCT06570434 | Tenet Medicines | Phase 1 / Phase 2 |
| Not Yet Recruiting | US Zamto-cel Autoimmune Diseases NCT06708845 | Miltenyi Biomedicine GmbH | Phase 1 |
| Recruiting | BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008 | Peking University People's Hospital | Phase 2 |
| Recruiting | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe NCT06711146 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | REACT-01: Reversing Autoimmunity Through Cell Therapy NCT06465147 | Seattle Children's Hospital | Phase 1 |
| Recruiting | Systemic Immune Inflammatory Index in Systemic Lupus Erythematosus NCT06796569 | Sohag University | — |
| Completed | This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients Wit NCT06698900 | AstraZeneca | — |
| Recruiting | Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects. NCT06657703 | HC Biopharma Inc. | Phase 1 |
| Withdrawn | Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases NCT06411639 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multi NCT06955598 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Se NCT06617325 | UCB Biopharma SRL | Phase 3 |
| Recruiting | Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus NCT06691152 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Not Yet Recruiting | A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus NCT06535412 | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB NCT05818254 | Duke University | N/A |
| Not Yet Recruiting | Different Aspects and Etiologies of Gastointestinal Bleeding in Patients With Systemic Lupus Erythematosus NCT06641427 | Assiut University | — |
| Recruiting | CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry NCT06804057 | CorEvitas | — |
| Recruiting | A Study of Obexelimab in Patients With Systemic Lupus Erythematosus NCT06559163 | Zenas BioPharma (USA), LLC | Phase 2 |
| Suspended | Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases NCT06549296 | Nanjing Bioheng Biotech Co., Ltd. | EARLY_Phase 1 |
| Recruiting | A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chines NCT06576271 | GlaxoSmithKline | Phase 1 |
| Withdrawn | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMES NCT06456567 | Vor Biopharma | Phase 3 |
| Not Yet Recruiting | Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus NCT06356740 | Hospices Civils de Lyon | Phase 2 |
| Completed | Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in R NCT06759519 | AstraZeneca | — |
| Recruiting | Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus NCT06421701 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 1 |
| Recruiting | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Aut NCT06434363 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus NCT06400537 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subj NCT06448273 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) NCT06350110 | Essen Biotech | Phase 1 / Phase 2 |
| Active Not Recruiting | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Betw NCT06293365 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Intervention to Improve Communication and Medication Adherence in Lupus NCT06458075 | Duke University | N/A |
| Recruiting | A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus NCT06518668 | Columbia University | Phase 1 |
| Recruiting | Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy NCT06544343 | University Of Perugia | N/A |
| Recruiting | Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients NCT06394063 | RenJi Hospital | N/A |
| Recruiting | Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease NCT05799378 | NYU Langone Health | Phase 3 |
| Recruiting | A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus NCT06106906 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Active Not Recruiting | REACH (Restore Energy, Activity Can Help) Lupus Study NCT06479213 | Tufts Medical Center | N/A |
| Recruiting | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic NCT06411249 | GlaxoSmithKline | Phase 4 |
| Not Yet Recruiting | The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Rati NCT06404723 | Sohag University | — |
| Unknown | A Model About the Response of Belimumab in SLE NCT04893161 | First Affiliated Hospital Xi'an Jiaotong University | Phase 4 |
| Recruiting | Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital NCT06449794 | Sohag University | — |
| Recruiting | Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases NCT06428188 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythema NCT06133972 | Novartis Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) NCT06340490 | Guangdong Ruishun Biotech Co., Ltd | Phase 1 |
| Recruiting | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell NCT06581562 | IRIS Research and Development, LLC | Phase 1 |
| Not Yet Recruiting | Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06417398 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Ac NCT06360068 | Qiong Fu | Phase 2 |
| Active Not Recruiting | Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) NCT06294236 | Sana Biotechnology | Phase 1 |
| Recruiting | An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease NCT06379646 | China Immunotech (Beijing) Biotechnology Co., Ltd. | N/A |
| Recruiting | Fatigue in Lupus Intervention Programmes (FLIP) NCT06308770 | University of Edinburgh | N/A |
| Recruiting | Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases NCT06361745 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | N/A |
| Recruiting | An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Par NCT05835310 | AstraZeneca | Phase 3 |
| Not Yet Recruiting | Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus NCT06297408 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Activ NCT06121297 | Cabaletta Bio | Phase 1 / Phase 2 |
| Withdrawn | A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) NCT06153095 | Lyell Immunopharma, Inc. | Phase 1 / Phase 2 |
| Unknown | (Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression NCT06255743 | Sohag University | N/A |
| Active Not Recruiting | Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus NCT06222853 | The Children's Hospital of Zhejiang University School of Medicine | Phase 1 |
| Recruiting | Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus NCT06333483 | Autolus Limited | Phase 1 |
| Unknown | The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus NCT06227559 | Assiut University | — |
| Unknown | Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals. NCT06228222 | Assiut University | — |
| Unknown | Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus NCT06378736 | Northwell Health | — |
| Recruiting | A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus NCT06106893 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Suspended | A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK434 NCT06188507 | GlaxoSmithKline | Phase 1 |
| Unknown | Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus. NCT06294483 | Sohag University | — |
| Recruiting | ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS NCT06593041 | University Hospital, Strasbourg, France | — |
| Completed | The Effect of Co-enzyme Q10 on the Clinical Outcome of Pediatric Patients With Systemic Lupus Erythematosus NCT07096557 | Ain Shams University | Phase 2 |
| Recruiting | Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE) NCT06458972 | Tongji Hospital | — |
| Terminated | Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006) NCT06161116 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Safety of the Herpes Zoster Subunit Vaccine in Lupus NCT05559671 | NYU Langone Health | Phase 4 |
| Recruiting | A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO750 NCT05835986 | Hoffmann-La Roche | Phase 1 |
| Recruiting | LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus NCT05714930 | Heinrich-Heine University, Duesseldorf | N/A |
| Recruiting | The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (S NCT05440422 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Unknown | Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus NCT06151990 | Assiut University | — |
| Completed | Efficacy of Synbiotic Supplementation on IL-10, TGF-B and Disease Activity in Systemic Lupus Erythematosus Pat NCT07048470 | Universitas Sriwijaya | N/A |
| Recruiting | Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis NCT06462768 | CHU de Reims | — |
| Terminated | Lupus Education Alliance Program NCT05243875 | Tulane University | N/A |
| Recruiting | Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases NCT06316076 | RenJi Hospital | Phase 1 |
| Completed | Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab i NCT06046534 | AstraZeneca | — |
| Unknown | AntiDFS70 Lupus Nephritis NCT06119763 | Sohag University | — |
| Completed | In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Al NCT05544448 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA NCT06056778 | AstraZeneca | — |
| Recruiting | A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Dise NCT05869955 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 |
| Recruiting | Systemic Lupus Erythematosus and Accelerated Aging NCT05698173 | University Hospital, Bordeaux | N/A |
| Unknown | Belimumab in SLE Synovial Inflammation and Lymph Nodes NCT06327724 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Terminated | A Study of Imvotamab in Severe Systemic Lupus Erythematosus NCT06041568 | IGM Biosciences, Inc. | Phase 1 |
| Unknown | Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients NCT05971498 | Assiut University | — |
| Recruiting | Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Im NCT05859191 | University Hospital, Tours | — |
| Recruiting | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants Wit NCT05843643 | AbbVie | Phase 3 |
| Recruiting | Assessment of Physician Consideration of EPRO's, from Patients with Gout, Rheumatoid Arthritis, Sjogren's Synd NCT05927688 | University Hospital, Strasbourg, France | — |
| Recruiting | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease NCT06347718 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Completed | A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus NCT05917288 | GlaxoSmithKline | Phase 1 |
| Unknown | Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia NCT05929248 | Guanmin Gao | Phase 2 |
| Recruiting | Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythem NCT05916781 | Chinese SLE Treatment And Research Group | Phase 4 |
| Active Not Recruiting | A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Sy NCT05856448 | Galapagos NV | Phase 2 |
| Completed | A Study of DS-7011a in Patients With Systemic Lupus Erythematosus NCT05638802 | Daiichi Sankyo | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus NCT05796206 | Beijing Mabworks Biotech Co., Ltd. | Phase 2 |
| Unknown | Anti-CD20 Antibodies for Treatment of SLE-PAH NCT05828147 | Chinese SLE Treatment And Research Group | Phase 4 |
| Recruiting | Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Mul NCT07215754 | University of Pisa | — |
| Completed | A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus NCT05687526 | RemeGen Co., Ltd. | Phase 1 |
| Active Not Recruiting | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases NCT05879419 | University of Sao Paulo General Hospital | Phase 4 |
| Unknown | Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus NCT05900232 | Sohag University | N/A |
| Unknown | Immunogenicity, Reactogenicity of Shingrix in SLE NCT06001606 | Seoul National University Hospital | Phase 3 |
| Recruiting | Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neur NCT05880121 | IRCCS San Raffaele | — |
| Active Not Recruiting | A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus NCT05866861 | Cugene Inc. | Phase 1 |
| Active Not Recruiting | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythem NCT05624749 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus NCT05791799 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 / Phase 3 |
| Active Not Recruiting | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With System NCT05639114 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic NCT05798117 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice NCT05637112 | AstraZeneca | — |
| Unknown | CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus NCT05765006 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| Recruiting | Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Eryt NCT05339217 | Liu Tian | Phase 3 |
| Unknown | Screening Biomarkers for Severe Lupus Based on Multi-omics Studies NCT05539001 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Recruiting | Biomarkers in Inflammatory Rheumatic Diseases Diagnosis NCT06778343 | Universidade Nova de Lisboa | — |
| Completed | Periodontal Status in Patients With Chronic Skin Diseases NCT06073613 | University of Medicine and Pharmacy at Ho Chi Minh City | — |
| Active Not Recruiting | A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Particip NCT05620407 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Activ NCT05617677 | Bristol-Myers Squibb | Phase 3 |
| Unknown | Serum Levels of Angiotensin Converting Enzyme in Systemic Lupus Erythematous Patients NCT05516511 | Sohag University | — |
| Unknown | fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus NCT06226324 | The Affiliated Hospital of Inner Mongolia Medical University | — |
| Unknown | Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients NCT05666336 | Fen Li | Phase 4 |
| Unknown | Effect of Applying Ujjayi Pranayama on Cortisol in Lupus Patients NCT05748899 | Badr University | N/A |
| Terminated | Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus NCT05306873 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headach NCT05613582 | Indonesia University | N/A |
| Unknown | Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus NCT06137053 | Yanfeng Hou | — |
| Unknown | A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus NCT05465707 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Unknown | Laser Acupuncture in Egyptian Systemic Lupus Females With Insulin Resistance NCT05632029 | Cairo University | N/A |
| Unknown | The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment NCT05631717 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 3 |
| Unknown | Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) NCT05704153 | Hospital Clinic of Barcelona | N/A |
| Active Not Recruiting | The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) NCT05540327 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 2 |
| Unknown | The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity NCT05689580 | Chang Gung Memorial Hospital | N/A |
| Completed | Vagus Nerve Stimulation for Systemic Lupus Erythematous NCT05315739 | Rigshospitalet, Denmark | N/A |
| Recruiting | Safety of Administering Isoniazid to SLE Patients to Prevent TB NCT06618573 | Universitas Padjadjaran | Phase 2 / Phase 3 |
| Not Yet Recruiting | Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus NCT05424627 | Central Hospital, Nancy, France | — |
| Unknown | Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit NCT05418855 | Assiut University | — |
| Terminated | A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMES NCT05306574 | Vor Biopharma | Phase 3 |
| Completed | Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology NCT05116163 | Brigham and Women's Hospital | N/A |
| Completed | Probiotics in Systemic Lupus Erythematosus NCT05433857 | Ain Shams University | Phase 2 |
| Terminated | Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension St NCT05430854 | Amgen | Phase 2 |
| Completed | Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus NCT05392790 | Cairo University | N/A |
| Completed | Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus NCT05247203 | RemeGen Co., Ltd. | Phase 1 |
| Recruiting | Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine NCT00775476 | State University of New York - Upstate Medical University | Phase 2 |
| Completed | ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation) NCT05347992 | DxTerity Diagnostics | — |
| Recruiting | Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidat NCT04751396 | M.D. Anderson Cancer Center | — |
| Unknown | Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Eryth NCT05262686 | Peking University People's Hospital | Phase 3 |
| Completed | Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients NCT05478018 | Rigshospitalet, Denmark | N/A |
| Completed | The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW) NCT05162586 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Completed | Effects of Telehealth Initiative on Lupus Patients NCT05329831 | Selcuk University | N/A |
| Unknown | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases NCT05236491 | Paul R Fortin | Phase 2 / Phase 3 |
| Terminated | A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Er NCT05123586 | Eli Lilly and Company | Phase 2 |
| Unknown | Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus NCT05179018 | Assiut University | — |
| Unknown | Prediction of Lupus Renal Flares Study NCT05362812 | Charite University, Berlin, Germany | — |
| Unknown | Laser Puncture and Program of Lifestyle Modification in Lupus Females NCT05381545 | Cairo University | N/A |
| Unknown | Evaluation Of Serum MIF Level in SLE Patients NCT05253638 | Assiut University | N/A |
| Completed | A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects NCT05203692 | Daiichi Sankyo | Phase 1 |
| Completed | Stress, Inflammation and Immune Response Pilot Study- Aim 3 NCT04857151 | University of Wisconsin, Madison | EARLY_Phase 1 |
| Terminated | PRV-3279-2a Trial in Systemic Lupus NCT05087628 | Provention Bio, a Sanofi Company | Phase 2 |
| Completed | Motivating Individuals With Lupus to Exercise NCT05287581 | University of Michigan | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Adminis NCT05155345 | Hoffmann-La Roche | Phase 1 |
| Completed | Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythe NCT05426902 | Duke University | N/A |
| Completed | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's NCT05001737 | Swedish Orphan Biovitrum | Phase 3 |
| Unknown | Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients NCT05105217 | Assiut University | — |
| Active Not Recruiting | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus NCT05039840 | Sanofi | Phase 2 |
| Completed | A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously NCT05328557 | Cugene Inc. | Phase 1 |
| Unknown | Sequential Belimumab and T-cell Based Therapy in SLE NCT04447053 | National University Hospital, Singapore | Phase 4 |
| Unknown | Treatment of Periodontal Disease in Systemic Lupus Erythematosus NCT04046172 | University College, London | N/A |
| Completed | Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19 NCT05115370 | University of Nottingham | — |
| Unknown | The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephr NCT05132621 | Medical University of Warsaw | — |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus NCT04963296 | Hoffmann-La Roche | Phase 3 |
| Completed | Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lup NCT04908865 | GlaxoSmithKline | Phase 4 |
| Unknown | Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Re NCT05358652 | Fundacin Biomedica Galicia Sur | — |
| Active Not Recruiting | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Sys NCT04895696 | Bristol-Myers Squibb | Phase 2 |
| Unknown | IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage NCT05045417 | Sohag University | — |
| Active Not Recruiting | Centrally Acting ACE Inhibition in SLE NCT04486118 | Northwell Health | Phase 2 |
| Unknown | PRediction Of Flares In Lupus With autoantibodiEs and Chemokines NCT04951427 | UMC Utrecht | — |
| Unknown | Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus NCT05057481 | Assiut University | Phase 3 |
| Completed | Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Particip NCT04971590 | GlaxoSmithKline | — |
| Unknown | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Ery NCT05030779 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflamma NCT04902807 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Unknown | The Effect of Deep Breathing and Transcutaneus Electrical Nerve Stimulation on Heart Rate Variability NCT05157334 | Aalborg University Hospital | N/A |
| Unknown | Exercise and Nutrition Recommendations for Patients Using Glucocorticoids (ENRG) NCT05090189 | Bruno Gualano | N/A |
| Recruiting | ILD-SARDs Registry and Biorepository NCT05007340 | McGill University Health Centre/Research Institute of the McGill University Health Centre | — |
| Completed | A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus NCT04882878 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE) NCT05001698 | AstraZeneca | Phase 1 |
| Enrolling By Invitation | A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lup NCT04976322 | UCB Biopharma SRL | Phase 3 |
| Recruiting | Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions NCT04833465 | Children's National Research Institute | — |
| Unknown | RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome NCT03684564 | University College, London | Phase 2 |
| Unknown | Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study NCT04942314 | Jia Deng | — |
| Unknown | An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematos NCT04810754 | Charite University, Berlin, Germany | Phase 2 |
| Completed | ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus NCT04835441 | Alpine Immune Sciences Inc, A Subsidiary of Vertex | Phase 2 |
| Active Not Recruiting | Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus NCT04877691 | AstraZeneca | Phase 3 |
| Unknown | Expression of CXCR4 in Patients With Systemic Lupus Erythematosus NCT04799730 | Sohag University | — |
| Unknown | Recombinant Zoster Vaccine in Stable SLE Patients NCT04516408 | RenJi Hospital | N/A |
| Unknown | At the Heart of the Matter - Speckle Tracking Echocardiography in Lupus Mothers and Their Offspring NCT05451277 | Evelyne Vinet | — |
| Active Not Recruiting | Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vasc NCT04276701 | University Hospital, Bordeaux | N/A |
| Completed | Efficacy and Safety of Belimumab in SLE Patients NCT04515719 | RenJi Hospital | Phase 4 |
| Active Not Recruiting | Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus NCT04582136 | Chinese SLE Treatment And Research Group | Phase 3 |
| Unknown | Study of Leukocyte Populations in Patients With Chronic Inflammatory NCT04749875 | Assistance Publique - Hôpitaux de Paris | — |
| Terminated | COVID-19 Vaccination in Rheumatic Disease Patients NCT04839315 | Mayo Clinic | EARLY_Phase 1 |
| Unknown | Objective Measurement With TCM Pattern for AIDDES NCT04747288 | Taipei Veterans General Hospital, Taiwan | — |
| Unknown | Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc NCT05292456 | Hacettepe University | — |
| Not Yet Recruiting | Belimumab in Patients With Systemic Lupus Erythematosus NCT04671706 | Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Fundación Española de Medicina | — |
| Unknown | Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Diseas NCT04558814 | Assiut University | N/A |
| Terminated | A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus NCT04700267 | Galapagos NV | Phase 1 |
| Completed | Transcriptional and Immune Parameters of Response to Belimumab NCT04570306 | Biomedical Research Foundation, Academy of Athens | — |
| Completed | Study of M5049 in CLE and SLE Participants NCT04647708 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 1 |
| Completed | Healthy Lifestyle Intervention in Patients with Systemic Lupus Erythematosus: the Living Well with Lupus Study NCT04431167 | University of Sao Paulo | N/A |
| Unknown | Epigenetics in Lupus Nephritis NCT04648059 | University of Göttingen | — |
| Unknown | Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus NCT04532541 | Children's Hospital of Fudan University | — |
| Unknown | The Effectiveness of Walking in Patients With Systemic Lupus Erythematosus NCT04983784 | Dalin Tzu Chi General Hospital | N/A |
| Completed | O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus NCT04440566 | University Hospital, Bordeaux | N/A |
| Recruiting | Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation NCT04320680 | University Hospital, Brest | N/A |
| Completed | The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata NCT04239521 | Momentum Data | — |
| Completed | Individual Patient Exposure and Response in Pediatric Lupus NCT04358302 | Duke University | N/A |
| Unknown | Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases NCT06029335 | University of Pecs | — |
| Completed | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) NCT04433585 | Nektar Therapeutics | Phase 2 |
| Completed | The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases NCT04397107 | The First Hospital of Jilin University | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Se NCT04294667 | UCB Biopharma SRL | Phase 3 |